BeiGene announced that the first doses of Brukinsa have been administered for the treatment of adult patients with chronic lymphocytic leukemia, or CLL, to patients in Armenia and Nepal, as part of a three-year collaboration to provide access to the medicine in 29 low- and middle-income countries.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BGNE:
- BeiGene announces FDA accelerated approval of BRUKINSA
- BeiGene announces new efficacy analysis comparing Brukinsa vs. Acalabrutinib
- BeiGene price target lowered to $345 from $350 at Guggenheim
- BeiGene price target raised to $235 from $224 at TD Cowen
- BeiGene’s Biologics License Application for tevimbra accepted by FDA